Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

OBJECTIVES:

Primary

• To determine progession free survivial rates in patients with inoperable stage IA and select stage IB non-small cell lung cancer treated with external-beam radiation therapy and radiofrequency ablation (RFA).

Secondary

• To determine the acute and late toxicity of combining RFA with external-beam radiation therapy.
• To determine the patterns of failure at time of first relapse.
• To determine the rate of overall survival at 1 and 2 years after treatment.
• To evaluate the ability of peak standard uptake value (SUV) and max SUV obtained prior to RFA to predict local control and time to progression.
• To measure post RFA/simulation (treatment planning) PET max and peak SUV's and correlate this data with local control at 1 and 2 years.
• To evaluate the ability of peak and max SUV's for fludeoxyglucose F 18 obtained shortly after radiotherapy (post-treatment) to predict local control and time to progression.
• To evaluate PET-CT data and its utility in guiding radiation therapy treatment planning.
• To explore the use of dual time point imaging PET data obtained to predict local control and also to differentiate between recurrence versus inflammation when applicable.
• To assess physical function as a prognostic measure, and to determine the impact of treatment on physical function.
• To evaluate the impact of treatment on generic and disease-specific quality of life.

OUTLINE: Patients undergo fludeoxyglucose F18 positron emission tomography (FDG-PET) and CT scan at baseline. Patients then undergo radiofrequency ablation (RFA). Beginning within 5 weeks after completion of RFA, patients undergo external-beam radiation therapy once daily, 5 days a week, for 5-6 weeks. FDG-PET/CT scan is repeated 3-4 weeks after RFA and 12-16 weeks after completion of external-beam radiation therapy.

Quality of life is assessed at baseline, during treatment, and at 16 weeks and at 1 year after completion of treatment.

After completion of study treatment, patients are followed periodically for 2 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed non-small cell lung cancer

• Cytology or biopsy-proven disease
• Stage IA (T1N0M0) or select stage IB (T2N0M0 because of visceral pleural involvement or size ≥ 3.0 cm)
• Tumor size ≤ 3.5 cm
• No bronchioloalveolar carcinoma
• Node-negative patients will have hilar or mediastinal lymph nodes ≤ 1.5 cm and no clinically suspicious uptake on fludeoxyglucose F 18 (FDG)-PET in those areas

• Patients with > 1.5 cm lymph nodes and clinically suspicious FDG-PET uptake will still be eligible if directed tissue biopsy or needle aspiration of abnormally identified area are negative for cancer
• Patients with > 1.5 cm and < 2.0 cm lymph nodes and no clinically suspicious FDG-PET uptake in those areas will still be eligible
• All patients are required to have been evaluated by a thoracic surgeon and have either refused surgery or been deemed medically inoperable due to comorbid conditions
• CT images of the chest must be reviewed by an experienced interventional radiologist and the target lesion must be determined to be in a location where radiofrequency ablation is technically achievable based on the proximity of adjacent organs and structures
• Any patient with suspected M1 disease based on pre-treatment PET-CT imaging should have biopsy if possible

• If the biopsy is positive, the patient should be treated as per the clinician's preference off of this protocol
• If the biopsy is negative and representative of the lesion in question then the patient may be treated as per this protocol
• If the biopsy is non-diagnostic, consideration should be given to repeat biopsy
• If the repeat biopsy remains non-diagnostic or a biopsy is not feasible than the patient will not be eligible for this protocol and should be treated per the clinician's preference

PATIENT CHARACTERISTICS:

• Inclusion Criteria:

• ECOG performance status 0-2
• Women of childbearing potential must have a negative pregnancy test
• Fertile women must use effective contraception
• Exclusion Criteria:

• History of prior malignancy within the past 2 years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, T1N0 squamous cell carcinoma of the larynx, or localized prostate cancer with a current PSA level < 1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to study entry
• Pregnant or lactating women

PRIOR CONCURRENT THERAPY:

• Exclusion Criteria:

• Previous chest radiation to the lung or mediastinum
• Patients must not receive other concurrent anticancer therapies while on protocol including any of the following:

• Radiotherapy
• Radiofrequency ablation
• Other antineoplastic interventional radiology techniques
• Chemotherapy
• Biological therapy
• Vaccine therapy
• Surgery

• Surgical treatment of nonmelanomatous skin cancer or ≤ T1 urothelial cell carcinoma allowed